The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2020-01-23 20:58:432021-09-09 15:22:29Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00neilhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgneil2019-11-12 19:45:002021-09-09 15:22:38Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2019-10-29 18:25:002021-09-09 15:22:45Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-07-16 19:58:222021-09-09 15:22:52Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00altusdevsite_4grsdfhttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svgaltusdevsite_4grsdf2018-06-11 07:58:232021-09-09 15:22:59Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee
/in press releases /by altusdevsite_4grsdfThe American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain
/in references (CGS-200-5) /by neilNews coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
Presentation: A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
/in presentations /by neilView the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract
Press Release: Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
/in press releases /by altusdevsite_4grsdfVizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
Press Release: Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
/in press releases /by altusdevsite_4grsdfVizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200
/1 Comment/in press releases /by altusdevsite_4grsdfPress Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]